Financial Ratios West Pharmaceutical Services, Inc.
Equities
WST
US9553061055
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 304.41 USD | +0.50% |
|
-5.55% | +10.64% |
| 16/05 | West Pharmaceutical says making progress in restoring global operations after cyberattack | RE |
| 15/05 | West Pharma says operations recovering after cyberattack | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 15.64 | 13.78 | 11.85 | 9.93 | 10.09 | |||||
Return on Total Capital | 19.7 | 16.86 | 14.25 | 12.01 | 12.3 | |||||
Return On Equity % | 31.59 | 23.34 | 21.32 | 17.71 | 16.85 | |||||
Return on Common Equity | 31.59 | 23.34 | 21.32 | 17.71 | 16.85 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 41.52 | 39.36 | 38.31 | 34.51 | 35.91 | |||||
SG&A Margin | 12.68 | 10.95 | 12 | 11.58 | 12.68 | |||||
EBITDA Margin % | 31.3 | 30.63 | 28.6 | 25.89 | 26.35 | |||||
EBITA Margin % | 27.17 | 26.59 | 24.06 | 20.64 | 20.87 | |||||
EBIT Margin % | 26.98 | 26.46 | 23.94 | 20.52 | 20.78 | |||||
Income From Continuing Operations Margin % | 23.37 | 20.3 | 20.12 | 17.03 | 16.06 | |||||
Net Income Margin % | 23.37 | 20.3 | 20.12 | 17.03 | 16.06 | |||||
Net Avail. For Common Margin % | 23.37 | 20.3 | 20.12 | 17.03 | 16.06 | |||||
Normalized Net Income Margin | 17.18 | 17.01 | 15.54 | 13.28 | 13.45 | |||||
Levered Free Cash Flow Margin | 7.32 | 8.54 | 6.66 | 7.15 | 8.91 | |||||
Unlevered Free Cash Flow Margin | 7.5 | 8.71 | 6.85 | 7.21 | 8.92 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.93 | 0.83 | 0.79 | 0.77 | 0.78 | |||||
Fixed Assets Turnover | 2.65 | 2.42 | 2.13 | 1.79 | 1.71 | |||||
Receivables Turnover (Average Receivables) | 6.48 | 5.62 | 5.58 | 5.22 | 5.29 | |||||
Inventory Turnover (Average Inventory) | 4.73 | 4.41 | 4.28 | 4.67 | 4.8 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 2.93 | 3.7 | 2.88 | 2.79 | 3.02 | |||||
Quick Ratio | 2.11 | 2.73 | 2.07 | 1.93 | 2.1 | |||||
Operating Cash Flow to Current Liabilities | 0.98 | 1.39 | 1.16 | 1.19 | 1.15 | |||||
Days Sales Outstanding (Average Receivables) | 56.35 | 64.94 | 65.41 | 70.17 | 68.99 | |||||
Days Outstanding Inventory (Average Inventory) | 77.12 | 82.69 | 85.19 | 78.4 | 76.04 | |||||
Average Days Payable Outstanding | 47.44 | 45.71 | 45.41 | 47.99 | 44.17 | |||||
Cash Conversion Cycle (Average Days) | 86.03 | 101.92 | 105.19 | 100.58 | 100.86 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 13.93 | 11.84 | 10.73 | 11.38 | 10.27 | |||||
Total Debt / Total Capital | 12.23 | 10.59 | 9.69 | 10.22 | 9.31 | |||||
LT Debt/Equity | 11.64 | 11.16 | 5.46 | 10.68 | 9.51 | |||||
Long-Term Debt / Total Capital | 10.22 | 9.98 | 4.93 | 9.59 | 8.62 | |||||
Total Liabilities / Total Assets | 29.52 | 25.77 | 24.77 | 26.38 | 25.62 | |||||
EBIT / Interest Expense | 93.17 | 96.68 | 78.47 | 197.87 | 1.28T | |||||
EBITDA / Interest Expense | 110.38 | 114.94 | 97.27 | 261.57 | 1.7T | |||||
(EBITDA - Capex) / Interest Expense | 79.48 | 78.91 | 57.04 | 135.9 | 1.13T | |||||
Total Debt / EBITDA | 0.36 | 0.35 | 0.35 | 0.39 | 0.38 | |||||
Net Debt / EBITDA | -0.48 | -0.63 | -0.62 | -0.23 | -0.55 | |||||
Total Debt / (EBITDA - Capex) | 0.5 | 0.51 | 0.6 | 0.75 | 0.58 | |||||
Net Debt / (EBITDA - Capex) | -0.67 | -0.92 | -1.06 | -0.44 | -0.82 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 31.89 | 1.95 | 2.18 | -1.92 | 6.25 | |||||
Gross Profit, 1 Yr. Growth % | 53.14 | -3.52 | -0.55 | -11.64 | 10.57 | |||||
EBITDA, 1 Yr. Growth % | 67.48 | -0.53 | -4.62 | -11.2 | 8.16 | |||||
EBITA, 1 Yr. Growth % | 81.25 | -0.61 | -7.52 | -15.86 | 7.42 | |||||
EBIT, 1 Yr. Growth % | 81.86 | -0.39 | -7.54 | -15.94 | 7.6 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 91.16 | -11.47 | 1.28 | -16.97 | 0.2 | |||||
Net Income, 1 Yr. Growth % | 91.16 | -11.47 | 1.28 | -16.97 | 0.2 | |||||
Normalized Net Income, 1 Yr. Growth % | 80.08 | 0.6 | -6.66 | -16.2 | 7.65 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 89.72 | -10.84 | 1.94 | -15.1 | 1.49 | |||||
Accounts Receivable, 1 Yr. Growth % | 26.91 | 3.99 | 1.87 | 7.93 | 1.82 | |||||
Inventory, 1 Yr. Growth % | 17.77 | 9.62 | 4.8 | -13.27 | 17.75 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 11.4 | 12.06 | 19.78 | 13.44 | 9.46 | |||||
Total Assets, 1 Yr. Growth % | 18.61 | 9.14 | 5.88 | -4.86 | 17.2 | |||||
Tangible Book Value, 1 Yr. Growth % | 28.58 | 16.2 | 7.74 | -6.96 | 19.21 | |||||
Common Equity, 1 Yr. Growth % | 25.93 | 14.97 | 7.3 | -6.9 | 18.41 | |||||
Cash From Operations, 1 Yr. Growth % | 23.6 | 23.97 | 7.25 | -15.85 | 15.52 | |||||
Capital Expenditures, 1 Yr. Growth % | 45.3 | 12.31 | 27.2 | 4.14 | -24.16 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -16.74 | 18 | -20.36 | 5.28 | 32.48 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -16.4 | 17.48 | -19.68 | 3.28 | 31.44 | |||||
Dividend Per Share, 1 Yr. Growth % | 6.15 | 5.8 | 5.48 | 5.19 | 4.94 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 24.06 | 15.96 | 2.07 | 0.11 | 2.09 | |||||
Gross Profit, 2 Yr. CAGR % | 39.33 | 21.65 | -2.05 | -6.26 | -1.16 | |||||
EBITDA, 2 Yr. CAGR % | 48.97 | 28.97 | -2.7 | -7.97 | -2 | |||||
EBITA, 2 Yr. CAGR % | 60.31 | 34.07 | -4.24 | -11.79 | -4.93 | |||||
EBIT, 2 Yr. CAGR % | 60.66 | 34.44 | -4.15 | -11.84 | -4.9 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 65.47 | 30.09 | -5.31 | -8.3 | -8.79 | |||||
Net Income, 2 Yr. CAGR % | 65.47 | 30.09 | -5.31 | -8.3 | -8.79 | |||||
Normalized Net Income, 2 Yr. CAGR % | 59.8 | 34.45 | -3.21 | -11.55 | -5.02 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 64.35 | 30.06 | -4.66 | -6.97 | -7.17 | |||||
Accounts Receivable, 2 Yr. CAGR % | 23.75 | 16.58 | 2.93 | 4.86 | 4.83 | |||||
Inventory, 2 Yr. CAGR % | 26.71 | 13.62 | 7.18 | -4.67 | 1.05 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 11.31 | 11.73 | 15.86 | 16.57 | 11.43 | |||||
Total Assets, 2 Yr. CAGR % | 18.97 | 13.78 | 7.5 | 0.37 | 5.59 | |||||
Tangible Book Value, 2 Yr. CAGR % | 23.86 | 22.23 | 11.89 | 0.12 | 5.32 | |||||
Common Equity, 2 Yr. CAGR % | 21.84 | 20.32 | 11.07 | -0.05 | 5 | |||||
Cash From Operations, 2 Yr. CAGR % | 26.11 | 23.79 | 15.31 | -5 | -1.41 | |||||
Capital Expenditures, 2 Yr. CAGR % | 41.59 | 27.75 | 19.52 | 15.09 | -11.13 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 12.19 | -0.77 | -3.32 | -8.43 | 18.1 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 11.78 | -0.8 | -3.12 | -8.92 | 16.51 | |||||
Dividend Per Share, 2 Yr. CAGR % | 6.36 | 5.98 | 5.64 | 5.34 | 5.07 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 18.14 | 16.2 | 11.17 | 0.72 | 2.12 | |||||
Gross Profit, 3 Yr. CAGR % | 29.18 | 23.33 | 13.75 | -5.35 | -0.95 | |||||
EBITDA, 3 Yr. CAGR % | 35.62 | 30.34 | 16.63 | -5.62 | -2.88 | |||||
EBITA, 3 Yr. CAGR % | 44.77 | 36.86 | 18.46 | -8.28 | -5.8 | |||||
EBIT, 3 Yr. CAGR % | 44.94 | 37.16 | 18.67 | -8.25 | -5.79 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 47.34 | 34.33 | 19.68 | -9.37 | -5.55 | |||||
Net Income, 3 Yr. CAGR % | 47.34 | 34.33 | 19.68 | -9.37 | -5.55 | |||||
Normalized Net Income, 3 Yr. CAGR % | 44.55 | 37.12 | 19.05 | -7.75 | -5.57 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 46.81 | 34.04 | 19.91 | -8.28 | -4.23 | |||||
Accounts Receivable, 3 Yr. CAGR % | 19.27 | 17.93 | 11.46 | 4.57 | 3.84 | |||||
Inventory, 3 Yr. CAGR % | 20.83 | 20.73 | 10.6 | -0.12 | 2.29 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 11.09 | 11.56 | 14.35 | 15.05 | 14.15 | |||||
Total Assets, 3 Yr. CAGR % | 18.75 | 15.6 | 11.08 | 3.21 | 5.69 | |||||
Tangible Book Value, 3 Yr. CAGR % | 20.14 | 21.25 | 17.2 | 5.22 | 6.12 | |||||
Common Equity, 3 Yr. CAGR % | 18.7 | 19.5 | 15.82 | 4.72 | 5.76 | |||||
Cash From Operations, 3 Yr. CAGR % | 26.48 | 25.39 | 18.01 | 3.81 | 1.4 | |||||
Capital Expenditures, 3 Yr. CAGR % | 34.26 | 31.07 | 27.56 | 14.16 | 0.15 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | 19.61 | 14.42 | -7.79 | -0.53 | 3.57 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | 18.9 | 13.96 | -7.54 | -1.03 | 2.92 | |||||
Dividend Per Share, 3 Yr. CAGR % | 6.58 | 6.17 | 5.81 | 5.49 | 5.2 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 13.41 | 12.54 | 11.43 | 9.48 | 7.44 | |||||
Gross Profit, 5 Yr. CAGR % | 18.58 | 17.24 | 15.68 | 10.51 | 7.53 | |||||
EBITDA, 5 Yr. CAGR % | 22.63 | 21.36 | 18.88 | 13.4 | 8.79 | |||||
EBITA, 5 Yr. CAGR % | 27.15 | 26.01 | 22.86 | 14.81 | 8.48 | |||||
EBIT, 5 Yr. CAGR % | 27.26 | 26.14 | 22.99 | 14.93 | 8.61 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 35.74 | 31.2 | 23.46 | 15.31 | 7.36 | |||||
Net Income, 5 Yr. CAGR % | 35.74 | 31.2 | 23.46 | 15.31 | 7.36 | |||||
Normalized Net Income, 5 Yr. CAGR % | 27.6 | 26.57 | 23.27 | 15.06 | 8.77 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 35.33 | 31.18 | 23.53 | 15.82 | 8.24 | |||||
Accounts Receivable, 5 Yr. CAGR % | 19.52 | 15.64 | 13.11 | 12.52 | 8.76 | |||||
Inventory, 5 Yr. CAGR % | 13.68 | 14.02 | 15.17 | 9.85 | 6.68 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 7.68 | 8.11 | 12.97 | 13.54 | 13.18 | |||||
Total Assets, 5 Yr. CAGR % | 14.06 | 14.19 | 14.12 | 9.25 | 8.85 | |||||
Tangible Book Value, 5 Yr. CAGR % | 17.31 | 17.34 | 16.77 | 12.31 | 12.29 | |||||
Common Equity, 5 Yr. CAGR % | 15.88 | 15.97 | 15.59 | 11.26 | 11.36 | |||||
Cash From Operations, 5 Yr. CAGR % | 21.63 | 22.42 | 21.89 | 12.22 | 9.82 | |||||
Capital Expenditures, 5 Yr. CAGR % | 8.29 | 16.82 | 28.16 | 24.43 | 10.39 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | 45.29 | 20.06 | 10.16 | 4.66 | 1.81 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 41.78 | 19.38 | 9.84 | 4.19 | 1.42 | |||||
Dividend Per Share, 5 Yr. CAGR % | 7.09 | 6.61 | 6.2 | 5.84 | 5.51 |
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















